Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Apr;19(4):313-4.
doi: 10.1634/theoncologist.2014-0091. Epub 2014 Mar 25.

Clinical trial results: a clinical trial bazaar!

Antonio Tito Fojo  1 , Susan E Bates
Affiliations
Editorial

Clinical trial results: a clinical trial bazaar!

Antonio Tito Fojo et al. Oncologist. 2014 Apr.

Abstract

The Oncologist’s Clinical Trial Results section welcomes both positive and negative results in an effort to share information, speed discovery, and inform the field. Clinical Trial Results submissions have shown how succinctly the salient features of a submission can be presented, with more in-depth information to be found online.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

None
Dr. Antonio Tito Fojo
None
Dr. Susan E. Bates
See this image and copyright information in PMC

References

    1. Moy B, Neven P, Lebrun F, et al. Bosutinib in combination with the aromatase inhibitor exemestane: A phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. The Oncologist. 2014;19:346–347. - PMC - PubMed
    1. Moy B, Neven P, Lebrun F, et al. Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. The Oncologist. 2014;19:348–349. - PMC - PubMed
    1. Plimack ER, Tan T, Wong Y-N, et al. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The Oncologist. 2014;19:354–355. - PMC - PubMed
    1. Toffalorio F, Spitaleri G, Catania C, et al. Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. The Oncologist. 2014;19:344–345. - PMC - PubMed
    1. Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. The Oncologist. 2014;19:350–351. - PMC - PubMed

Publication types